Linkedin-in Youtube Twitter Envelope

Our Pipeline

Building a pipeline to bring the promise of cell therapies to more patients

Pre-clinical
Phase 1
Phase 2/3¹
Pre-clinical
Phase 1
Phase 2/3¹

CHM 0201 (CORE-NK Platform)

Solid Tumours and Hematological Malignancies

LEARN MORE

CHM 0301 (Next Generation CORE-NK Platform)

Blood Cancers

LEARN MORE

CHM 1301 (CLTX CAR NK)

Solid tumours

LEARN MORE

CHM 2301 (CDH17 CAR NK)

Solid tumours

LEARN MORE

CHM 3301 (Undisclosed Target)

LEARN MORE

CHM 1101 (CLTX CAR T)

Glioblastoma

LEARN MORE

Melanoma

LEARN MORE

Colorectal

LEARN MORE

Prostate

LEARN MORE

CHM 2101 (CDH17 CAR T)

Neuroendocrine

LEARN MORE

Colorectal

LEARN MORE

Pancreatic

LEARN MORE

Gastric

LEARN MORE
¹ Phase 3 may not be required if Phase 2 is registrational

Clinical Trials

CHM 1101 (CLTX CAR T) Phase 1 Clinical Trial

Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma

CHM 1101 Phase 1 Clinical Trial

Phase 1 Clinical Trial
CHM 1101 Phase 1 Clinical Trial​
click the image to enlarge

CHM 1101 (CLTX CAR T)

Dosing Schema

Dosing Schema​
click the image to enlarge

CHM 1101 (CLTX CAR T)

Design

click the image to enlarge

Clinical Trials – CHM 0201

CHM 0201 (CORE-NK Platform)

CHM 0201 (CORE-NK Platform)
click the image to enlarge

CHM 0201 (CORE-NK Platform)

Dosing Schema
click the image to enlarge

CHM 0201 (CORE-NK Platform)

Treatment Schema
click the image to enlarge

Abstracts and Publications

A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma

Click on the icons below to download preferred medium
MP4
15MB		 PowerPoint
3.5 MB		 PDF
0.5 MB

 

Sign-up to our mailing list to receive all the latest news from Chimeric Therapeutics
 
Please fill out our form for Investor Relations Inquiries
Investor Contacts